Perspective Therapeutics reports interim clinical data from three radiopharmaceutical programs at ASCO 2026

Perspective Therapeutics, Inc.

VMT01 in melanoma: 2/7 confirmed responses (29%) at 3.0 mCi; 6/7 stable disease or partial response.
[212Pb]PSV359 advanced to Cohort 3 (6.0 mCi); no DLTs, grades 1-2 TEAEs only.
VMT-α-NET: deepened responses vs prior cut-offs; 10/23 (43%) Cohort 2 patients achieved response per RECIST v1.1.
All programs well-tolerated: no treatment-related discontinuations, no Grade 4/5 events across 68+ patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.